Latest & greatest articles for memantine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on memantine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on memantine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for memantine

41. Memantine in Alzheimer's disease

Memantine in Alzheimer's disease Executive Summary IQWiG Reports – Commission No. A05-19C Memantine in Alzheimer’s disease 1 1 Translation of the executive summary of the final report “Memantin bei Alzheimer Demenz” (Version 1.0; Status: 08.07.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-19C Memantine (...) in Alzheimer’s disease Version 1.0 08.07.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Memantine in Alzheimer’s disease Contracting agency: Federal Joint Committee Commission awarded on: 22.2.2005 Internal Commission No.: A05-19C Publisher’s address: Institute for Quality and Efficiency in Health Care Dillenburger Str. 27 51105 Cologne Germany Tel.: +49 221 35685-0 Fax: +49 221 35685-1 berichte@iqwig.de www.iqwig.de Institute for Quality and Efficiency

2009 Institute for Quality and Efficiency in Healthcare (IQWiG)

42. Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia Wong CL, Bansback N, Lee PE, Anis AH Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the incremental cost-effectiveness of cholinesterase inhibitors and memantine for mild-to-moderate vascular dementia. The authors concluded that, compared with standard care, cholinesterase inhibitors and memantine had small benefits in cognition and were all more costly. If an active treatment was approved, donepezil 10mg was the most cost-effective. There were a few limitations

2009 NHS Economic Evaluation Database.

43. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M CRD summary The review (...) concluded that cholinesterase inhibitors and memantine can result in statistically significant but clinically marginal improvement in measures of cognition and global assessment in patients with dementia. This review was generally well conducted and the authors' conclusions are likely to be reliable. Authors' objectives To determine the effectiveness of cholinesterase inhibitors and the neuropeptide-modifying agent memantine for the treatment of dementia. Searching Cochrane Central Register

2008 DARE.

44. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis

Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 DARE.

45. Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Full Text available with Trip Pro

Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: Cholinesterase inhibitors and memantine consistently but marginally improve symptoms of dementia Article Text Therapeutics Review: Cholinesterase inhibitors and memantine

2008 Evidence-Based Mental Health

46. Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Weycker D, Taneja C, Edelsberg J, Erder M H, Schmitt F A, Setyawan J, Oster G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the cost-effectiveness of adjuvant memantine in patients with moderate-to-severe Alzheimer’s disease, who were receiving stable doses of donepezil. The authors concluded that memantine plus donepezil improved the clinical outcomes and reduced the total costs of care

2007 NHS Economic Evaluation Database.

47. Meta-analysis of six-month memantine trials in Alzheimer's disease

Meta-analysis of six-month memantine trials in Alzheimer's disease Meta-analysis of six-month memantine trials in Alzheimer's disease Meta-analysis of six-month memantine trials in Alzheimer's disease Smith Doody R, Tariot P N, Pfeiffer E, Olin J T, Graham S M CRD summary This review compared memantine with placebo in the treatment of probable Alzheimer's disease (AD). The authors concluded that memantine is effective and safe across the spectrum of disease severity. The authors' conclusions (...) reflect the findings of the review for patients with moderate to severe AD and appear reliable. However, benefits were not reported for all outcomes in patients with mild to moderate AD. Authors' objectives To assess the efficacy and safety of memantine in Alzheimer's disease (AD), and to determine the effects in differing severities of disease. Searching MEDLINE, BIOSIS Previews, International Pharmaceutical Abstracts and the database of Forest Laboratories Inc. were searched in February 2005

2007 DARE.

48. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain

Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Antonanzas F, Rive B, Badenas J M, Gomez-Lus S, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study assessed the use of memantine in patients with Alzheimer's disease (AD). This treatment was compared with standard care, which the authors defined as no pharmacological treatment. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population

2006 NHS Economic Evaluation Database.

49. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A Record Status This is a bibliographic record of a published health technology assessment (...) from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Loveman E, Green C, Kirby J, Takeda A, Picot J, Payne E, Clegg A. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment 2006; 10(1): 1-176 Authors' objectives The objective of this review was to provide an update review of the best quality evidence for the clinical effectiveness and cost

2006 Health Technology Assessment (HTA) Database.

50. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease

Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease National Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. London: National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance 111. 2006 Authors' objectives This guidance constitutes a review of 'NICE technology appraisal guidance 19' on the use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately

2006 Health Technology Assessment (HTA) Database.

51. Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Full Text available with Trip Pro

Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Article Text Therapeutics Memantine plus donepezil improves physical and mental health in people

2005 Evidence-Based Mental Health

52. Memantine for treatment of moderate to severe Alzheimer's disease

Memantine for treatment of moderate to severe Alzheimer's disease Memantine for treatment of moderate to severe Alzheimer's disease Memantine for treatment of moderate to severe Alzheimer's disease Canadian Coordinating Office for Health Technology Assessment Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Coordinating Office (...) for Health Technology Assessment. Memantine for treatment of moderate to severe Alzheimer's disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4 Authors' objectives The aim of this report is to summarize the use of memantine (trademarked Ebixa, distributed by Lundbeck Canada Inc.)for the treatment of moderate to severe Alzheimer's disease. Authors' conclusions Health Canada has issued a Notice of Compliance with conditions for memantine in the treatment

2005 Health Technology Assessment (HTA) Database.

53. memantine hydrochloride

memantine hydrochloride CEDAC FINAL RECOMMENDATION on RECONSIDERATION and REASONS for RECOMMENDATION MEMANTINE (Ebixa - Lundbeck Canada Inc.) Description: Memantine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that, in part, inhibits activation of NMDA receptors by glutamate. Health Canada has granted memantine a Notice of Compliance with conditions as monotherapy or as adjunctive therapy with cholinesterase inhibitors for the symptomatic treatment of patients (...) with moderate to severe dementia of the Alzheimer’s type. Dosage Forms: 10 mg tablets. Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that memantine not be listed. Reasons for the recommendation: 1. The committee considered the efficacy findings from three randomized controlled trials (RCTs), two comparing memantine to placebo (24 - 28 weeks) and one comparing memantine plus donepezil to donepezil alone (24 weeks) in patients with moderate to severe Alzheimer’s disease (MMSE

2005 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

54. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective Jones R W, McCrone P, Guilhaume C Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health intervention studied was memantine (20mg/day), a moderate-affinity uncompetitive NMDA antagonist approved in the EU for the treatment of moderately severe-to-severe Alzheimer's disease. Type of intervention Treatment. Economic study type Cost-effectiveness

2004 NHS Economic Evaluation Database.

55. Memantine

Memantine Memantine Memantine Sangha K Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Sangha K. Memantine. University HealthSystem Consortium (UHC). Drug Monograph. 2004 Authors' objectives The UHC Drug Monographs are a continuing series of authoritative, concise evaluations of new and emerging pharmaceuticals. Monographs are written by drug information (...) literature and provides recommendations for appropriate use. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Memantine /therapeutic use Language Published English Country of organisation United States Address for correspondence University HealthSystem Consortium, 2001 Spring Rd., Suite 700, Oak Brook, IL 60523 USA. Tel: 630-954-1700; Fax: 630-954-4730; Email: travis@uhc.edu AccessionNumber 32006001056 Date bibliographic record published 13/09/2006 Date abstract record published 13

2004 Health Technology Assessment (HTA) Database.

56. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Full Text available with Trip Pro

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed.To compare (...) the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil.A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14, who received stable doses of donepezil, conducted at 37 US sites between June 11, 2001, and June 3, 2002. A total of 322 patients (80%) completed the trial.Participants were randomized to receive memantine (starting

2004 JAMA Controlled trial quality: predicted high

57. Namenda (Memantine HCI)

Namenda (Memantine HCI) Drug Approval Package: Namenda (Memantine HCI) NDA #021487 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Namenda (Memantine HCI) Tablets Company: Forest Laboratories Inc. Application No.: 021487 Approval Date: 10/16/2003 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Bioequivalence Review(s) (PDF) (PDF) (PDF) Administrative Document(s) (PDF) (PDF) (PDF

2003 FDA - Drug Approval Package

58. Memantine in moderate-to-severe Alzheimer's disease. (Abstract)

Memantine in moderate-to-severe Alzheimer's disease. Overstimulation of the N-methyl-D-aspartate (NMDA) receptor by glutamate is implicated in neurodegenerative disorders. Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of Alzheimer's disease.Patients with moderate-to-severe Alzheimer's disease were randomly assigned to receive placebo or 20 mg of memantine daily for 28 weeks. The primary efficacy variables were the Clinician's Interview-Based Impression of Change (...) also analyzed with only the observed values included, without replacing the missing values (observed-cases analysis).Two hundred fifty-two patients (67 percent women; mean age, 76 years) from 32 U.S. centers were enrolled. Of these, 181 (72 percent) completed the study and were evaluated at week 28. Seventy-one patients discontinued treatment prematurely (42 taking placebo and 29 taking memantine). Patients receiving memantine had a better outcome than those receiving placebo, according

2003 NEJM Controlled trial quality: uncertain

59. Memantine for Alzheimer's disease and vascular dementia - horizon scanning review

Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review Memantine for Alzheimer's disease and vascular dementia - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Memantine for Alzheimer's disease (...) and vascular dementia - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on memantine for Alzheimer's disease and vascular dementia. Authors' conclusions - Clinical impact: Memantine is the first treatment being developed for patients suffering from moderate to severe Alzheimer's disease and for patients suffering from vascular dementia. This is a growing patient group

2001 Health Technology Assessment (HTA) Database.